FDA Links Cubicin To Serious Strain Of Pneumonia

Law360, New York (July 30, 2010, 7:00 PM EDT) -- The U.S. Food and Drug Administration has warned patients and health care professionals that Cubicin, a Cubist Pharmaceuticals Inc. drug used to treat skin and blood infections, can cause a serious form of pneumonia in rare cases.

Cubicin, the branded form of the intravenous antibacterial drug daptomycin, can cause eosinophilic pneumonia, a rare type of the disease where white blood cells fill the lungs, the FDA said on Thursday.

The FDA found seven cases of eosinophilic pneumonia between 2004 and 2010 that were likely associated with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.